Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

February 22, 2023

https://www.globenewswire.com/news-release/2023/02/22/2612962/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2022-Results-and-Business-Updates.html

Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter

On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end

Read more at globenewswire.com

Related news for (EDIT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.